SLQT Q1 FY27: Narrower Loss, but Revenue Declines 15% as Cost Cuts Take Hold

What happened

SelectQuote's Q1 FY2027 results showed a narrower adjusted EBITDA loss, but revenue fell 15% year-over-year, underscoring continued contraction in the insurance distribution business. Management highlighted cost controls and profitability improvements ahead of the critical Medicare Advantage annual enrollment period, suggesting a focus on stabilizing margins rather than growth. The improvement aligns with the company's recent emphasis on operational efficiency, but the revenue decline is consistent with weaker policy volumes and lower carrier incentives flagged in prior filings. While the earnings call likely provided a more optimistic tone, the fundamentals remain challenged: high carrier concentration (63% of revenue from three carriers), thin interest coverage, and a still-unresolved NYSE listing compliance overhang. The cash flow quality concern persists, as prior working-capital tailwinds from supplier payment terms may not repeat, leaving the company dependent on the upcoming enrollment season to drive sustainable cash generation.

Implication

The narrower adjusted EBITDA loss is a modest positive signal that management's cost discipline is taking hold, but the 15% revenue decline indicates the core business is still shrinking, which could eventually pressure profitability if volumes continue to fall. The upcoming Medicare Advantage enrollment season is a key catalyst; strong policy submissions could reverse the revenue trend, but given the prior year's decline in submitted policies and lower carrier incentives, upside may be limited. The unresolved NYSE listing compliance remains a critical overhang that could force a reverse split or delisting, capping upside until an 8-K confirms regained compliance. Cash flow quality remains uncertain because the supplier payment terms benefit seen in prior quarters may not be repeatable, and the company's high debt load (effective interest ~10.2%) leaves little room for error. Therefore, investors should maintain a wait-and-see approach, looking for confirmation of listing compliance, a clean operating cash flow bridge, and evidence that SelectRx profitability is improving before considering a position.

Thesis delta

The news does not materially alter the WAIT thesis, as it confirms management's focus on profitability but also highlights ongoing revenue contraction. The narrower EBITDA loss is encouraging but insufficient to upgrade the rating without evidence of revenue stabilization and cash flow quality. The main catalysts remain NYSE compliance and the outcome of the Medicare Advantage enrollment season.